Cargando…
A review of osteoarthritis signaling intervention using small-molecule inhibitors
Numerous small-molecule inhibitors (SMIs) have been approved as adjuvant or first-line therapies for malignancies. Based on cancer treatment using SMIs, next-generation SMIs that can be used to optimize the therapeutic index, overcome drug resistance, and establish combination therapies are in devel...
Autores principales: | Park, Junyong, Lee, Sang Yeob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371536/ https://www.ncbi.nlm.nih.gov/pubmed/35960127 http://dx.doi.org/10.1097/MD.0000000000029501 |
Ejemplares similares
-
Small molecule inhibitors of osteoarthritis: Current development and future perspective
por: Liu, Dan, et al.
Publicado: (2023) -
Recent Advances in Small Molecule Inhibitors for the Treatment of Osteoarthritis
por: Lin, Jianjing, et al.
Publicado: (2023) -
Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
por: Zheng, Xiaohang, et al.
Publicado: (2022) -
A New Class of Small Molecule Inhibitor of BMP Signaling
por: Sanvitale, Caroline E., et al.
Publicado: (2013) -
Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
por: Voronkov, Andrey, et al.
Publicado: (2012)